Merck reports FDA approved Idvynso for treatment of HIV-1

Merck (MRK) announced that the U.S. Food and Drug Administration approved Idvynso, a new, two-drug single-tablet regimen of 100 mg doravirine and 0.25 mg islatravir, for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine. Idvynso is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers and lamivudine or emtricitabine. Idvynso will be available in pharmacies after May 11, the company stated.